With the deepening of the research on tumor pathogenesis, molecular targeted therapy has become a hot spot, such as tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) [4]. This evidence concerns the gene EGFR and neoplasm.